Zobrazeno 1 - 10
of 835
pro vyhledávání: '"Pik3ca mutation"'
Publikováno v:
Hereditary Cancer in Clinical Practice, Vol 22, Iss 1, Pp 1-7 (2024)
Abstract Background Somatic mutations in the EGFR gene occur in about 50% of non-small cell lung cancers, with the T790M mutation significantly contributing to secondary resistance against EGFR-TKI drugs. However, EGFR T790M germline mutations rarely
Externí odkaz:
https://doaj.org/article/801414aafb8f4b39bd0168cfc380ce9a
Autor:
A. V. Zyuzyukina, E. Yu. Yakunina, V. I. Borodulina, L. A. Vasilovskaya, E. V. Slepov, V. A. Komissarova, R. A. Zukov
Publikováno v:
Опухоли женской репродуктивной системы, Vol 20, Iss 2, Pp 48-54 (2024)
Aim. To identify population characteristics of the PIK3CA gene mutation among breast cancer patients in the Krasnoyarsk region.Materials and methods. The study included 140 patients with breast cancer with a certain mutation status of the PIK3CA gene
Externí odkaz:
https://doaj.org/article/e53f64da4966412db9bed72e7ef9fa18
Autor:
Alexander V. Sultanbaev, Irina V. Kolyadina, Konstantin V. Menshikov, Shamil I. Musin, Ainur F. Nasretdinov, Nadezda I. Sultanbaeva, Radmir R. Rakhimov, Danila O. Lipatov, Irina A. Menshikova, Adel A. Izmailov, Elena E. Lipatova
Publikováno v:
Современная онкология, Vol 26, Iss 1, Pp 65-72 (2024)
Background. The combination of alpelisib with fulvestrant is the optimal targeted endocrine therapy for patients with hormone-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with mutations in the PIK3CA gene. This regimen has been
Externí odkaz:
https://doaj.org/article/e3c845b4890840dc9606d4f6fb39fad8
Autor:
Ah Reum Lim, Boyeon Kim, Jwa Hoon Kim, Myung Han Hyun, Kyong Hwa Park, Yeul Hong Kim, Soohyeon Lee
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThis phase Ib study was performed to determine the safety of combination capecitabine with alpleisib (phosphatidylinositol 3-kinase catalytic subunit p110α blockade) and determine the maximal tolerated dose (MTD) and recommended phase ll d
Externí odkaz:
https://doaj.org/article/b8aae7bffb54466fa8eea9b57abb925c
Autor:
A. I. Stukan, T. Yu. Semiglazova, S. I. Kutukova, V. A. Porkhanov, V. N. Bodnya, E. N. Imyanitov, V. V. Antipova, Z. K. Khachmamuk, O. Yu. Chukhray, S. D. Maksimenko
Publikováno v:
Опухоли женской репродуктивной системы, Vol 19, Iss 4, Pp 63-74 (2024)
Background. Data on the prognostic role of the PIK3CA mutation in hormone receptor-positive (HR+) HER2-negative (HER2–) breast cancer (BC) are contradictory; nevertheless, there are indications of its negative predictive and prognostic significance
Externí odkaz:
https://doaj.org/article/88640b6bad6447928620a2997b883c2b
Publikováno v:
Open Medicine, Vol 18, Iss 1, Pp 610-21 (2023)
To determine whether ultrasound (US) features of breast cancer are associated with Breast Imaging and Reporting Data System molecular subtype, histologic grade, and hormone receptor status as well as to assess the predictive value of these features.
Externí odkaz:
https://doaj.org/article/052aa85422e446f78093513c871fb9a0
Autor:
Ribnikar Domen, Horvat Valentina Jeric, Ratosa Ivica, Veitch Zachary W, Grcar Kuzmanov Biljana, Novakovic Srdjan, Langerholc Erik, Amir Eitan, Seruga Bostjan
Publikováno v:
Radiology and Oncology, Vol 57, Iss 2, Pp 220-228 (2023)
The aim of the study was to evaluate the independent prognostic role of PIK3CA activating mutations and an association between PIK3CA activating mutations and efficacy of adjuvant endocrine therapy (ET) in patients with operable invasive lobular carc
Externí odkaz:
https://doaj.org/article/27d77d976ea540fdaf685c5bf50b066f
Autor:
Ye Hu, Fengxi Chen, Siwen Sun, Lingzhi Xv, Xueqing Wang, Meiling Wang, Shanshan Zhao, Zuowei Zhao, Man Li
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
This study aimed to explore the efficacy and potential mechanisms of rechallenge therapy with microtubule-targeting agents (MTAs) in patients with HER2-low metastatic breast cancer (MBC). We performed a systematic review to investigate the rechalleng
Externí odkaz:
https://doaj.org/article/7e288d93a73a4df0b2de9a54e8aa6ba0
Autor:
Katherine E. Hutchinson, Jessica W. Chen, Heidi M. Savage, Thomas J. Stout, Frauke Schimmoller, Javier Cortés, Susan Dent, Nadia Harbeck, William Jacot, Ian Krop, Sally E. Trabucco, Smruthy Sivakumar, Ethan S. Sokol, Timothy R. Wilson
Publikováno v:
Genome Medicine, Vol 15, Iss 1, Pp 1-14 (2023)
Abstract Background Mutations in the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K), encoded by the PIK3CA gene, cause dysregulation of the PI3K pathway in 35–40% of patients with HR+/HER2– breast cancer. Preclinically, cancer c
Externí odkaz:
https://doaj.org/article/6a84c1824dfc43c99cd063f56d446e86
Publikováno v:
Translational Oncology, Vol 37, Iss , Pp 101738- (2023)
Background: This study aimed to comprehensively explore the clinical significance of PIK3CA mutation in human epidermal growth factor receptor 2 (HER2)-positive breast cancer treated with anti-HER2 therapy. Methods: We systematically searched PubMed,
Externí odkaz:
https://doaj.org/article/7148fd04cc1745dda664bbb9d4006537